Intermittent phototherapy for treatment of neonatal jaundice
Not Applicable
- Conditions
- Health Condition 1: P599- Neonatal jaundice, unspecified
- Registration Number
- CTRI/2020/11/028934
- Lead Sponsor
- Defence Research and Development Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
•All late preterm (>= 35 weeks) and term neonates who need phototherapy for treatment of neonatal hyperbilirubinemia as per AAP guidelines (Low and Medium risk groups) either during birth hospitalization or readmitted after discharge in the first two weeks
Exclusion Criteria
High risk group as per AAP Guidelines
Onset of jaundice in the first 24 hours after birth
TSB in the exchange range at enrollment
Hemolytic jaundice (positive direct coombs test, evidence of hemolysis on peripheral blood smear or reticulocyte count > 6%)
Any neonate admitted in NICU
Major congenital malformations
Direct hyperbilirubinemia (direct bilirubin > 15% of total or > 1.0 mg/dl)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary: To compare the rate of decline of bilirubin (difference between bilirubin at enrolment and at end of phototherapy divided by duration of phototherapy) between neonates treated with intermittent versus continuous phototherapy. <br/ ><br>Timepoint: At start of phototherapy, 12-hourly intervals and at end of phototherapy.
- Secondary Outcome Measures
Name Time Method Secondary: To compare the duration of phototherapy, failure of phototherapy, side effects of phototherapy, duration of hospital stay, breastfeeding rates and parental satisfaction between neonates treated with intermittent versus continuous phototherapy. <br/ ><br>Timepoint: During treatment with phototherapy. Duration of hospital stay